| Document |
Document Title |
|
WO/2024/078413A1 |
Disclosed in the present invention are an acryloyl formate compound for LED photopolymerization, and a preparation method therefor and a use thereof. The acryloyl formate compound can be used as an initiator for LED photopolymerization. ...
|
|
WO/2024/049979A3 |
Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.
|
|
WO/2024/075535A1 |
In the present invention, there is employed a resist composition having, as a base resin, a polymer compound that has constituent units derived from a compound expressed by general formula (a0−m). In the formula, W is a polymerizable-g...
|
|
WO/2024/073845A1 |
The present application relates to methods for expanding hematopoietic stem cells (HSC) and/or hematopoietic progenitor cells (HPC) ex vivo and/or in vivo. The methods comprise culturing the HSCs and/or HPCs in the presence of a selectiv...
|
|
WO/2024/067816A1 |
The present invention relates to the field of drug delivery, and specifically relates to a pegylated lipid containing a lysine core and capable of being used as a drug carrier component, a lipid composition containing the pegylated lipid...
|
|
WO/2024/065054A1 |
The application pertains to a biocide composition comprises an EDTA derivative of Formula (I) in which a hydrophobic moiety is covalently bound to the EDTA, and a photo sensitizer and/or a liquid carrier. Methods for inhibiting microbial...
|
|
WO/2024/067639A1 |
The present invention relates to the field of biomedicine. Disclosed are an ionizable lipid compound having high transfection efficiency and a use thereof. The ionizable lipid compound is a compound having the following structure: formul...
|
|
WO/2024/063095A1 |
The prevent invention provides a radiolabeled tyrosine derivative which has excellent LAT1 selectability, higher retention at a tumor or cancer site, and a degree of clearance that does not cause side effects, and which can be safely man...
|
|
WO/2024/060373A1 |
Provided are a (+)-flurbiprofen salt derivative, a compound represented by the following formula (I), a method for preparing same, a pharmaceutical composition thereof, and use thereof.
|
|
WO/2024/061204A1 |
The present disclosure relates to a method for preparing a 2-hydroxyethyl aminocaproate compound and use thereof. Specifically, the present disclosure provides a method for preparing a compound of formula (I) or a salt thereof. The metho...
|
|
WO/2024/058665A1 |
The invention relates to the field of medicinal chemistry and radiopharmaceuticals, in particular to means, methods and cassettes for the automated synthesis of the radiotracer 6-L-[18F]fluoro-3,4- dihydroxyphenylalanine (6-L-[18F]FDOPA)...
|
|
WO/2024/058216A1 |
Provided is a metal extraction agent for extracting metal ions present in an aqueous phase into an oil phase, wherein nitrogen atoms positioned at both ends of a molecular chain constituting the metal extraction agent do not constitute a...
|
|
WO/2024/055116A1 |
This invention relates to the field of dermatology and cosmetology and describes methods of using small molecule chemical compounds and formulations thereof to reduce the appearance of rhytids and wrinkles. These methods and formulations...
|
|
WO/2024/054400A1 |
Crystalline 4-((L-valyl)oxy)butanoic acid, methods of preparing crystalline 4-((L- valyl)oxy)butanoic acid, pharmaceutical compositions of crystalline 4-((L-valyl)oxy)butanoic acid, and methods of treatment using crystalline 4-((L-valyl)...
|
|
WO/2024/051825A1 |
Provided are a cationic lipid and a preparation method therefor, a lipid composition containing the cationic lipid, and an LNP-pharmaceutical composition containing the lipid composition and a preparation of the LNP-pharmaceutical compos...
|
|
WO/2024/053091A1 |
[Problem] The purpose of the present invention is to develop a low-cost and higher aspect ratio material that is available as a substitute for conventional high aspect ratio magnesium hydroxide which requires a large amount of a monocarb...
|
|
WO/2024/049979A2 |
Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.
|
|
WO/2024/046955A1 |
The present invention relates to a process for preparing p-aminobenzoic acid-2-ethylhexyl ester comprising reacting p-nitrobenzoic acid-2-ethylhexyl ester with hydrogen in the presence of a catalyst, wherein the reaction is performed in ...
|
|
WO/2024/046786A1 |
The present invention deals with a process for preparing a solid, storage stable composition comprising at least one aminocarboxylate complexing agent.
|
|
WO/2024/047227A1 |
The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical c...
|
|
WO/2024/044147A1 |
Provided herein are methods for purifying an ionizable amino lipid (IAL) composition comprising impurities that may react with polynucleotides, such as mRNA. Methods for purifying IAL compositions comprise one or more scavenging-removal ...
|
|
WO/2024/037520A1 |
Disclosed in the present invention are a new compound as represented by general formula I, a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer and a racemate thereof, and a pharmaceutical composition containing the compo...
|
|
WO/2024/038835A1 |
A desulfurizing agent according to the present disclosure removes a sulfur compound from a sulfur compound-containing raw material. The desulfurizing agent is characterized by comprising a metal-organic structure, wherein: the metal-orga...
|
|
WO/2024/032611A1 |
Provided is a drug delivery system, which in particular relates to a lipid composition. The shown lipid composition comprising a therapeutic agent and/or a prophylactic agent such as RNA can be used for delivering the therapeutic agent a...
|
|
WO/2024/032753A1 |
Disclosed are a nitrogen-containing chain compound, a preparation method therefor, a composition containing said compound, and a use thereof. Provided is a nitrogen-containing chain compound as represented by formula (I) or a pharmaceuti...
|
|
WO/2024/033705A1 |
Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions...
|
|
WO/2024/034666A1 |
A ruthenium complex according to one aspect of the present disclosure is represented by general formula (1). In general formula (1), R1 represents a hydrogen atom, a phenyl group, or a monovalent substituent which is obtained by substitu...
|
|
WO/2024/027789A1 |
Disclosed are a cationic lipid compound as represented by formula (I) and composition for nucleic acid delivery, and a use. Also disclosed are a use of nano-lipid particles using said compound as a key component in the aspect of nucleic ...
|
|
WO/2024/016075A1 |
An oral liquid composition comprising an effective amount of an amino acid selected from L-tyrosine and L-tryptophan; a carbohydrate, water, and optionally one or more acceptable excipients, wherein the carbohydrate is at a % by weight o...
|
|
WO/2024/014325A1 |
An aromatic compound configured from a stable isotope, wherein two adjacent carbon atoms are 13C, the nuclear spin quantum number of the other atoms to which the two adjacent carbon atoms bond is 0, and a hydrogen atom that has a spin co...
|
|
WO/2024/012537A1 |
The present invention relates to the technical field of new pesticide compounds, and disclosed are a compound containing a triazolinone structure, and the use thereof and an herbicide. The compound has the structure as represented by for...
|
|
WO/2023/198200A9 |
The present disclosure provides a conjugate. The conjugate comprises one or more delivery groups and one or more functional groups. Each of the delivery groups is independently connected to the functional group by means of a covalent bon...
|
|
WO/2024/011238A2 |
Provided herein are compounds and compositions that inhibit production of trimethylamine (TMA), and methods of using the compounds, e.g., for inhibiting production of trimethylamine, and for treating disorders associated with conversion ...
|
|
WO/2024/003032A1 |
The invention relates to a method for obtaining an aminobenzoic acid or an aliphatic saturated C4- 6-dicarboxylic acid from an aqueous solution, comprising: A) producing the organic acid, wherein a) the organic acid is crystallised from ...
|
|
WO/2024/000920A1 |
Disclosed in the present invention is a method for preparing a β-trifluoromethylenamine compound on the basis of organic dye catalysis. The present invention belongs to the technical fields of the synthesis of medicines, pesticide produ...
|
|
WO/2024/003671A1 |
A formulation for decreasing aldehyde content in a polymeric material includes a compound which includes at least three moieties of formula (A) wherein each moiety (A) includes an amine moiety (-NH2) bonded ortho or meta to the amide moi...
|
|
WO/2024/006701A1 |
A method for preparing dialkyl amino acid ester sulfonates having reduced levels of byproducts, particularly sulfonic acid ester and dialkyl ether, is disclosed. The method involves reacting an amino acid having at least two carboxylic a...
|
|
WO/2023/250197A2 |
The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, st...
|
|
WO/2023/246074A1 |
Provided in the present invention are a cationic lipid compound used for nucleic acid delivery, a composition and a use. The compound is as shown in the following formula (I). Further provided in the present invention are the use of the ...
|
|
WO/2023/246747A1 |
Provided in the present invention are a cationic lipid compound and a composition for delivery of a nucleic acid, and the use. The compound is represented by the following formula (I). Further provided in the present invention are the us...
|
|
WO/2023/245463A1 |
Provided is a composition comprising A) a thiopyridinone compound; and B) a chelating agent selected from succinic acid derivatives, such as ethylenediamine disuccinic acid, and a salt thereof.
|
|
WO/2023/241577A1 |
The present application relates to the field of drug carriers, and specifically discloses a cationic lipid compound, and a preparation method therefor and a use thereof. The cationic lipid compound comprises a compound represented by for...
|
|
WO/2023/242424A1 |
The present invention relates to new carbohydrate derivatives ((O) and (l-oxide). The derivatives can be prepared via a method that involves direct amination. The derivatives can be used for various applications, for instance as surfacta...
|
|
WO/2023/242181A1 |
The invention discloses a method for obtaining crystalline diethylamino hydroxybenzoyl hexyl benzoate (I) comprising steps (a) to (d), (a) providing a feed comprising diethylamino hydroxybenzoyl hexyl benzoate (I) and at least a first cr...
|
|
WO/2023/240081A1 |
Provided herein are methods of treating, ameliorating, and/or preventing inflammatory diseases or disorders by administering to an afflicted subject a composition comprising ornithine, or a derivative thereof. Also provided are methods o...
|
|
WO/2023/236953A1 |
Disclosed are a nitrogen-containing chain compound, a preparation method, a composition containing said compound, and a use thereof. Provided is a nitrogen-containing chain compound represented by formula (I) or a pharmaceutically accept...
|
|
WO/2023/230702A1 |
Screening for novel antibacterial compounds in small molecule libraries has a low success rate. Here, we applied a machine learning (ML)-based virtual screening for antibacterial activity and evaluated its predictive power by experimenta...
|
|
WO/2023/232148A1 |
Provided in the present invention is a new amino acid-based cationic lipid containing unsaturated bonds, the structure of which is as shown in general formula (1), and the definitions of each symbol in the formula is consistent with thos...
|
|
WO/2023/232147A1 |
The present invention provides a novel amino acid cationic lipid, having a structure as shown in general formula (1), the definition of symbols therein being consistent with that in the text. The amino acid cationic lipid is a lipid that...
|
|
WO/2023/235386A1 |
This invention relates to the compositions and methods of synthesizing water-soluble cannabinoid prodrugs that are conjugated with amino acids, amino sugars, and aminosulfonic acid derivatives through a carbamate linker. The invention al...
|
